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Objectives: To describe a clinical case of Acinetobacter
baumannii sequence type (ST) 32 harbouring a New Delhi metallo-
β-lactamase (NDM) in Ecuador.
Methods: We used multilocus sequence typing (MLST) to
confirm the bacterial species and the sequence type of an
A. baumannii isolate. We used synergy with the imipenem–EDTA
disc method and the carbapenem inactivation method (CIM) to
determine carbapenemase production; the presence of a
carbapenemase gene was confirmed by PCR amplification and
amplicon sequencing.
Results: Molecular characterization revealed the presence of A.
baumannii ST32 harbouring the blaNDM-1 gene in Ecuador. The
blaNDM-1 gene was isolated through PCR and amplified from a
purified plasmid.
Conclusions: To the best of our knowledge, this is the first
report of A. baumannii ST32 harbouring the blaNDM-1 gene.
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E-mails: jorgereyes83@gmail.com, jareyesc@uce.edu.ecThe New Delhi metallo-β-lactamase (NDM) is a transferable
molecular class B carbapenemase (zinc metallo-β-lactamase)
reported in Sweden in 2008 in a Klebsiella pneumoniae isolate
from an Indian patient [1]. To date, NDM carbapenemases have
been reported in most regions around the world owing to the
rapid dissemination of the gene between members of the
Enterobacteriaceae and Acinetobacter spp. in human and envi-
ronmental isolates [2–4].
In Latin America and the Caribbean, NDM carbapenemase
has been detected in many isolates of A. baumannii (Brazil,
Colombia, and Honduras), A. bereziniae (Argentina, Brazil) and
A. pittii (Paraguay) [5]. We recently reported the presence of
the blaNDM-1 gene in A. baumannii in Ecuador without further
information on the isolate [6]. Here, we report the laboratory
and clinical context of a blaNDM-1 gene from A. baumannii
sequence type (ST) 32 infecting an English patient traveling from
Amsterdam to Ecuador.
After a 4-hour flight, a 59-year-old man presented psy-
chomotor agitation with a deterioration in his state of con-
sciousness that progressed with time. The patient had a
history of atrial fibrillation which was under treatment. When
he arrived in Ecuador, he was immediately assisted and
transferred to the emergency ward at the Hospital de los
Valles in Quito. He presented a Glasgow Coma Score (GCS)
of 5/15 and developed an ischaemic stroke requiring a tra-
cheostomy and gastrostomy at the intensive care unit (ICU).
On day 2 of hospitalization he developed an acute tracheo-
bronchitis associated with mechanical ventilation. A tracheal
aspirate and blood samples were sent to the laboratory and
an empirical antibiotic therapy of ampicillin–sulbactam (3 g
intravenously every 6 h) was initiated. A culture of tracheal
aspirate revealed Serratia marcescens and the antimicrobial
therapy was changed to piperacillin–tazobactam (4.5 g
intravenously every 6 h). Twelve days after hospitalization of
the patient, Pseudomonas aeruginosa was isolated from a blood
sample and the same antibiotic regimen was continued owing
to in vitro susceptibility of the P. aeruginosa strain. On day 15
the patient developed fever (37.9°C), and a peripheral central
venous catheter, a catheter tip, and urine samples were sentNew Microbe and New Infect 2019; 29: 100526
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TABLE 1. Clinical milestones during patient treatment in Ecuador. Antibiotic treatment was initiated according to the Hospital de
los Valles scheme of susceptibility. Acinetobacter baumannii infection started on day 15 after hospitalization (bold)
Historical
record Date Clinical manifestations Location Antibiotic treatment Comments
Day 1 15 May Psychomotor agitation with deterioration





Diagnosis of ischaemic stroke requiring
mechanical ventilation, tracheostomy
and gastrostomy
Day 3 17 May Suspected diagnosis of ventilator-associated pneumonia
(VAP). Empirical antibiotic treatment initiated
ICU Ampicillin/sulbactam
(3 g i.v. every 6 h)
Tracheal aspirate and blood
samples sent to laboratory
Day 7 21 May Serratia marcescens isolated from tracheal aspirate culture ICU Piperacillin/tazobactam
(4.5 g i.v. every 6 h)
Day 12 26 May Pseudomonas aeruginosa isolated from blood culture.
Same antibiotic regimen
ICU Piperacillin/tazobactam
(4.5 g i.v. every 6 h)
Day 15 29 May The patient developed fever (37.9°C), white blood cells =
11,400 cells/μL, procalcitonin = 0.48 ng/mL (ascending)
ICU Meropenem (1 g i.v. every 8 h) Peripheral, central venous catheter,
catheter tip, blood and urine samples
sent to laboratory
Day 18 1 June A. baumannii isolated from blood samples ICU Meropenem (1 g i.v. every 8 h)
Colistin (100 mg i.v. every 8 h)
Absence of urinary or respiratory
reinfections
Day 27 10 June Patient’s clinical condition improved Meropenem (1 g i.v. every 8 h)
Colistin (100 mg i.v. every 8 h)
Patient transferred to London
2 New Microbes and New Infections, Volume 29 Number C, May 2019 NMNIto the laboratory because of a suspicion of septicaemia
(Table 1). Microbiological cultures revealed carbapenem-
resistant A. baumannii (Vitek 2; bioMérieux). At this point,
the piperacillin–tazobactam combination was changed to
meropenem (1 g intravenously every 8 h) followed by colistin
(100 mg intravenously every 8 h) and strict infection control
measures (emphasizing contact precautions) were
implemented.
The isolate was submitted to the National Reference Labo-
ratory of Antimicrobial Resistance (Instituto Nacional de
Investigación en Salud Pública ‘Leopoldo Izquieta Perez’, Quito-
Ecuador) for molecular analysis of the resistance genes. The
A. baumannii strain was identified by polymerase chain reaction
(PCR) of blaOXA-51-like and gyrB genes, which confirmed the
species of bacterium. Antimicrobial susceptibility testing was
conducted using the disk diffusion method and automated
testing (Vitek2 AST-N272). Results revealed resistance to cef-
tazidime (MIC 64 μg/mL), cefepime (MIC 64 μg/mL), imipenem
(MIC 8 μg/mL), meropenem (MIC 16 μg/mL),
piperacillin–tazobactam (MIC 128/4 μg/mL), intermediate
resistance to ampicillin–sulbactam (MIC 16/8 μg/mL), and
susceptibility to gentamicin (MIC 1 μg/mL), ciprofloxacin
(MIC 1 μg/mL), tigecycline (MIC 2 μg/mL), and colistin (MIC 0.5
μg/mL) according to Acinetobacter spp. breakpoints [7].
Phenotypic screening for carbapenemase production using
EDTA [8] showed a synergy between imipenem and mer-
openem discs; moreover, the carbapenem inactivation method
(CIM) was positive. Screening for carbapenemase genes (blaKPC,
blaIMP, blaNDM, blaVIM, blaSIM, blaPER, blaVEB, blaGIM, blaGES) by
PCR revealed the presence of blaNDM; the 947-base-pair
amplicon was sequenced and confirmed as blaNDM-1 allele
(Genebank accession no: MF038874). The exploration of class
D β-lactamases (blaOXA-23-like, blaOXA-24-like, blaOXA-58-like© 2019 The Author(s). Published by Elsevier Ltd, NMNI, 29, 100526
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceand blaOXA-143) using a protocol based on Woodford et al.
(2006) [9,10] yielded negative results. Conjugation assays with
Escherichia coli J53 as the recipient bacterium and trans-
formation experiments with E. coli DH5α strain failed; however,
we amplified blaNDM-1 from purified plasmid DNA (extracted
with PureYield™ Plasmid Miniprep System and separated by
electrophoresis), suggesting that the blaNDM-1 gene is located in
a plasmid. A multilocus sequence typing (MLST) analysis of the
A. baumannii strain based on the Pasteur Institute scheme
(http://www.pasteur.fr) was performed and showed the profile
cpn60 (1), fusA (1), gltA (2), pyrG (2), recA (3), rplB (4), rpoB (4),
indicating that the isolate belonged to the sequence type 32
(ST32).
On day 27 the patient was discharged from the ICU due to
an improvement in his clinical condition. His treatment
continued with meropenem (1 g intravenously every 8 h) fol-
lowed by colistin (100 mg intravenously every 8 h) and was
immediately transferred to London with contact precautions
and the appropriate medical care.
To the best of our knowledge, this is the first description of
A. baumannii ST32 harbouring the blaNDM-1 gene in Ecuador and
possibly in the world; interestingly, previous reports highlight
the importance of carbapenem-resistant A. baumanni clonal
complex 32 (ST32, ST28, ST138) as a new emerging interna-
tional clone IV with epidemic potential [11]. No similar isolates
have been detected in this healthcare centre; however, the
patient had recognized risk factors associated with this type of
infection (mechanical ventilation, previous antibiotic exposure,
ICU hospitalization), which may indicate that this was a local
infection in a foreign patient (Table 1), adding more evidence
for the endemicity of NDM-1 in Ecuadorian hospitals [6,12].
We were unable to demonstrate the transferability of blaNDM-1
in the present case. Similarly, pNDM-BJ01-like plasmidsnses/by-nc-nd/4.0/).
NMNI Villacís et al. NDM-1 in Acinetobacter baumannii, Ecuador 3harbouring blaNDM genes were recently reported in Acineto-
bacter spp. [13]; in some of them the conjugation-related genes
are truncated or deleted, which affects their mobilization [14].
Detection of metallo-β-lactamases should continue to be
prioritized since the hazards of multiple resistance genes
spreading in multiple bacterial species is an undetected reality
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